

## Your commitment to quality of care is one we proudly share

That's why we created **GREAT**, the Global Registry for Endovascular Aortic Treatment, to evaluate real-world performance and inform future clinical practice.

Over a decade in the making.  
Nearly 5,000 patients.  
Over 30 publications.

### 5-YEAR TEVAR UPDATE

#### Evidence with real-life relevance

LARGE COHORT

## 578 TEVAR patients treated

with the GORE® TAG® Conformable Thoracic Endoprosthesis

LONG TERM

10-year follow-up planned

REAL-WORLD POPULATION\*

44% off-label TEVAR cases<sup>1</sup>

// GREAT provides a picture of the real-world use of [GORE® TAG® Conformable Thoracic Endoprosthesis] in TEVAR for the treatment of multiple thoracic aortic pathologies."

Ascending arch

## 4.5%

n = 26

Type B dissection

## 35.1%

n = 203

Descending thoracic  
aortic aneurysm

## 41.3%

n = 239

See the data



\* Age requirement and indication for aortic stent graft repair as determined by the treating physician.

# Durable performance across thoracic dissection and aneurysmal pathologies



Through 5 years, the GORE® TAG® Conformable Thoracic Stent Graft showed sustained safety and efficacy in real-world practice.<sup>1</sup>

## GREAT outcomes at-a-glance

### ZERO

Fractures  
Device compressions


### FAVORABLE

Freedom from all-cause mortality  
Aortic-related mortality  
Procedure survival 99.7%


### LOW RATES<sup>1</sup>

Stroke  
Paralysis  
Reintervention  
Serious TYPE III endoleaks\*  
Migration†

#### All-cause mortality by pathology



#### Aortic-related mortality by pathology



An endovascular approach for treatment of all thoracic aortic pathologies using the [GORE® TAG® Conformable Thoracic Endoprosthesis] can be accomplished in a “real-world” setting with low peri-procedural risk and a favorable freedom from aortic-related mortality long-term through 5 years.<sup>1</sup>

\* Only serious endoleaks are reported in GREAT (i.e., those meeting the ISO141155 definition of a Serious Adverse Event).

† Only 1 device migration was seen over this time frame.

# We build evidence, so you can build confidence

Designed to reflect real-world use, GREAT enriches the evidence at your disposal.

The current study reports a large cohort of thoracic pathology outcomes for TEVAR of up to 60 months. This data fills a gap of knowledge on long-term outcomes to date for this patient population over a long follow-up period, supporting ongoing use of endovascular therapy.<sup>1</sup>

5-year  
analysis 

Access data 

## References

1. Gable DR, Verhoeven E, Trimarchi S, et al.; GREAT Investigators. Endovascular treatment for thoracic aortic disease from the Global Registry for endovascular aortic treatment. *Journal of Vascular Surgery* 2024;79(5):11044-1056.e1.

 Consult Instructions  
for Use  
[eifu.goremedical.com](http://eifu.goremedical.com)

**INDICATIONS FOR USE IN THE U.S.:** The GORE® TAG® Thoracic Stent Graft is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac/femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac/femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only

Products listed may not be available in all markets.

GORE, Together, improving life, TAG and designs are trademarks of W. L. Gore & Associates, Inc.  
© 2024 W. L. Gore & Associates, Inc. 24AR1002-EN AUGUST 2024

W. L. Gore & Associates, Inc.  
[goremedical.com](http://goremedical.com)

Asia Pacific +65 67332882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

